Search

Your search keyword '"Alchalby, Haefaa"' showing total 50 results
Start Over Author "Alchalby, Haefaa"
50 results on '"Alchalby, Haefaa"'

1. Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation

Author

Kröger, Nicolaus, Panagiota, Victoria, Badbaran, Anita, Zabelina, Tatjana, Triviai, Ioanna, Araujo Cruz, Michelle Maria, Shahswar, Rabia, Ayuk, Francis, Gehlhaar, Marten, Wolschke, Christine, Bollin, Robin, Walter, Carolin, Dugas, Martin, Wiehlmann, Lutz, Lehmann, Ulrich, Koenecke, Christian, Chaturvedi, Anuhar, Alchalby, Haefaa, Stadler, Michael, Eder, Matthias, Christopeit, Max, Göhring, Gudrun, Koenigsmann, Michael, Schlegelberger, Brigitte, Kreipe, Hans-Heinrich, Ganser, Arnold, Stocking, Carol, Fehse, Boris, Thol, Felicitas, and Heuser, Michael

Published
2017
Full Text
View/download PDF

6. CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies

Author

Klyuchnikov, Evgeny, El-Cheikh, Jean, Sputtek, Andreas, Lioznov, Michael, Calmels, Boris, Furst, Sabine, Chabannon, Christian, Crocchiolo, Roberto, Lemarié, Claude, Faucher, Catherine, Bacher, Ulrike, Alchalby, Haefaa, Stübig, Thomas, Wolschke, Christine, Ayuk, Francis, Reckhaus, Marie-Luise, Blaise, Didier, and Kröger, Nicolaus

Published
2014
Full Text
View/download PDF

7. Impact of High-Risk Cytogenetics and Achievement of Molecular Remission on Long-Term Freedom from Disease after Autologous–Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Author

Kröger, Nicolaus, Badbaran, Anita, Zabelina, Tatjana, Ayuk, Francis, Wolschke, Christine, Alchalby, Haefaa, Klyuchnikov, Evgeny, Atanackovic, Djordje, Schilling, Georgia, Hansen, Timon, Schwarz, Sabine, Heinzelmann, Marion, Zeschke, Silke, Bacher, Ulrike, Stübig, Thomas, Fehse, Boris, and Zander, Axel R.

Published
2013
Full Text
View/download PDF

19. Allogeneic Stem Cell Transplantation for Myelofibrosis with Leukemic Transformation: A Study from the Myeloproliferative Neoplasm Subcommittee of the CMWP of the European Group for Blood and Marrow Transplantation

Author

Alchalby, Haefaa, Zabelina, Tatjana, Stübig, Thomas, van Biezen, Anja, Bornhäuser, Martin, Di Bartolomeo, Paolo, Beelen, Dietrich, Cahn, Jean Yves, Dreger, Peter, Schroyens, William, de Witte, Theo, Olavarria, Eduardo, and Kröger, Nicolaus

Published
2014
Full Text
View/download PDF

21. Impact of Molecular Genetics on Disease-Free Survival in Myelofibrosis Patients Following Allogeneic Stem Cell Transplantation

Author

Kroeger, Nicolaus, primary, Panagiota, Victoria, additional, Zabelina, Tatjana, additional, Araujo Cruz, Michelle Maria, additional, Shahswar, Rabia, additional, Badbaran, Anita, additional, Triviai, Ioanna N, additional, Ayuk, Francis, additional, Gehlhaar, Marten, additional, Wolschke, Christine, additional, Bollin, Robin, additional, Lehmann, Ulrich, additional, Koenecke, Christian, additional, Chaturvedi, Anuhar, additional, Alchalby, Haefaa, additional, Stadler, Michael, additional, Eder, Matthias, additional, Christopeit, Maximilian, additional, Göhring, Gudrun, additional, Koenigsmann, Michael, additional, Schlegelberger, Brigitte, additional, Kreipe, Hans Heinrich, additional, Ganser, Arnold, additional, Fehse, Boris, additional, Thol, Felicitas, additional, and Heuser, Michael, additional

Published
2015
Full Text
View/download PDF

22. Impact of Minimal Residual Disease after Allografting Detected By JAK2V617F, MPL or Calreticulin in Myelofibrosis Patients

Author

Kroeger, Nicolaus, primary, Badbaran, Anita, additional, Zabelina, Tatjana, additional, Christopeit, Maximilian, additional, Wolschke, Christine, additional, Ayuk, Francis, additional, Zander, Axel R., additional, Alchalby, Haefaa, additional, Bacher, Ulrike, additional, Triviai, Ioanna N, additional, and Fehse, Boris, additional

Published
2015
Full Text
View/download PDF

23. Dynamic of Bone Marrow Fibrosis Regression Predicts Survival after Allogeneic Stem Cell Transplantation for Myelofibrosis

Author

Kroeger, Nicolaus, Zabelina, Tatjana, Alchalby, Haefaa, Stuebig, Thomas, Wolschke, Christine, Ayuk, Francis, von Huenerbein, Natascha, Kvasnicka, Hans-Michael, Thiele, Juergen, Kreipe, Hans-Heinrich, Buesche, Guntram, Kroeger, Nicolaus, Zabelina, Tatjana, Alchalby, Haefaa, Stuebig, Thomas, Wolschke, Christine, Ayuk, Francis, von Huenerbein, Natascha, Kvasnicka, Hans-Michael, Thiele, Juergen, Kreipe, Hans-Heinrich, and Buesche, Guntram

Abstract

We correlate regression of bone marrow fibrosis (BMF) on day 30 and 100 after dose- reduced allogeneic stem cell transplantation (allo-SCT) in 57 patients with primary or post-essential thrombocythemia/polycythemia vera myelofibrosis with graft function and survival. The distribution of International Prognostic Scoring System (IPSS) risk score categories was 1 patient with low risk, 5 patients with intermediate-1 risk, 18 patients with intermediate-2 risk, and 33 patients with high risk. Before allo-SCT, 41 patients (72%) were classified as XXX [myclofibrosis (MF)]-3 and 16 (28%) were classified as MF-2 according to the World Health Organization criteria. At postengraftment day +30 (+/- 10 days), 21% of the patients had near-complete or complete regression of BMF (MF-0/-1), and on day +100 ( 20 days), 54% were MF-0/-1. The 5-year overall survival rate at day +100 was 96% in patients with MF-0/-1 and 57% for those with MF-2/-3 (P = .04). There was no difference in BMF regression at day +100 between IPSS high-risk and low/intermediate-risk patients. Complete donor cell chimerism at day +100 was seen in 81% of patients with MF-0/-1 and in 31% of those with MF-2/-3. Patients with MF-2/-3 at day +100 were more likely to be transfusion-dependent for either RBCs (P = .014) or platelets (P = .018). Rapid BMF regression after reduced-intensity conditioning allo-SCT resulted in a favorable survival independent of IPSS risk score at transplantation. (C) 2014 American Society for Blood and Marrow Transplantation.

Published
2014

24. Prognostic Impact of Splicing Factor Mutations in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Author

Panagiota, Victoria, primary, Heuser, Michael, additional, Araujo Cruz, Michelle Maria, additional, Badbaran, Anita, additional, Shahswar, Rabia, additional, Triviai, Ioanna N, additional, Fehse, Boris, additional, Alchalby, Haefaa, additional, Lehmann, Ulrich, additional, Koenecke, Christian, additional, Chaturvedi, Anuhar, additional, Stadler, Michael, additional, Eder, Matthias, additional, Göhring, Gudrun, additional, Koenigsmann, Michael, additional, Schlegelberger, Brigitte, additional, Kreipe, Hans Heinrich, additional, Ganser, Arnold, additional, Thol, Felicitas, additional, and Kröger, Nicolaus, additional

Published
2014
Full Text
View/download PDF

25. Survival of Allogeneic Stem Cell Transplantation Vs Conventional Therapies per DIPSS Stratification in Patients with Primary Myelofibrosis Younger Than 65 Years: A Retrospective Analysis on 673 Patients

Author

Kröger, Nicolaus, primary, Giorgino, Toni, additional, Scott, Bart L, additional, Ditschkowski, Marcus, additional, Alchalby, Haefaa, additional, Cervantes, Francisco, additional, Vannucchi, Alessandro M., additional, Cazzola, Mario, additional, Morra, Enrica, additional, Zabelina, Tatjana, additional, Maffioli, Margherita, additional, Pereira, Arturo, additional, Beelen, Dietrich, additional, Deeg, H. Joachim, additional, and Passamonti, Francesco, additional

Published
2014
Full Text
View/download PDF

31. Quality Of Life After Allogeneic Stem Cell Transplantation In Patients With Myelofibrosis (CMWP of EBMT)

Author

Machate, Nora, primary, Alchalby, Haefaa, additional, Sehner, Susanne, additional, Zabelina, Tatjana, additional, Wolff, Daniel, additional, Kobbe, Guido, additional, Bornhäuser, Martin, additional, Baurmann, Herrad, additional, Bethge, Wolfgang A, additional, Wulf, Gerald, additional, Zander, Axel R., additional, and Kröger, Nicolaus, additional

Published
2013
Full Text
View/download PDF

34. Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy

Author

Oyekunle, Anthony, primary, Zander, Axel R., additional, Binder, Mascha, additional, Ayuk, Francis, additional, Zabelina, Tatjana, additional, Christopeit, Maximilian, additional, Stübig, Thomas, additional, Alchalby, Haefaa, additional, Schafhausen, Philippe, additional, Lellek, Heinrich, additional, Wolschke, Christine, additional, Müller, Ingo, additional, Bacher, Ulrike, additional, and Kröger, Nicolaus, additional

Published
2012
Full Text
View/download PDF

35. Effective Prevention of Acute and Chronic Graft-Versus-Host Disease with Anti-Lymphocyte Globulin (ATG) without Increase of Relapse in HLA-Identical Sibling Peripheral Blood Stem Cell Transplantation.

Author

Kröger, Nicolaus, primary, Zabelina, Tatjana, additional, Ayuk, Francis, additional, Alchalby, Haefaa, additional, Wolschke, Christine, additional, Stübig, Thomas, additional, Klyuchnikov, Evgeny, additional, Berger, Jürgen, additional, and Zander, Axel R., additional

Published
2012
Full Text
View/download PDF

36. Impact of ASXL1 Mutations On Outcome After Reduced Intensity Allograft in Patients with Myelofibrosis

Author

Kröger, Nicolaus, primary, Koenecke, Christian, additional, Alchalby, Haefaa, additional, Zabelina, Tatjana, additional, Bollin, Robin, additional, Gehlhaar, Marten, additional, Dobbernack, Vera, additional, Kade, Sofia, additional, Huang, Liu, additional, Ganser, Arnold, additional, Ayuk, Francis, additional, Wolschke, Christine, additional, Thol, Felicitas, additional, and Heuser, Michael, additional

Published
2012
Full Text
View/download PDF

37. Achievement of Sustained Molecular Remission Induces Long-Term Freedom From Disease After Autologous-Allogeneic Tandem Transplantation in Patients with Multiple Myeloma

Author

Kröger, Nicolaus, primary, Zabelina, Tatjana, additional, Ayuk, Francis, additional, Wolschke, Christine, additional, Alchalby, Haefaa, additional, Badbaran, Anita, additional, Atanackovic, Djordje, additional, Schilling, Georgia, additional, Sezer, Orhan, additional, Bacher, Ulrike, additional, Stübig, Thomas, additional, Fehse, Boris, additional, and Zander, Axel R., additional

Published
2011
Full Text
View/download PDF

38. Long Term Follow-up of the Prospective Multicenter Study of reduced-Intensity Allogeneic Stem Cell Transplantation for Primary or Post ET/PV Myelofibrosis

Author

Alchalby, Haefaa, primary, Zabelina, Tatjana, additional, Wolff, Daniel, additional, Kobbe, Guido, additional, Bornhäuser, Martin, additional, Baurmann, Herrad, additional, Nagler, Arnon, additional, Bethge, Wolfgang A., additional, Stelljes, Matthias, additional, Uharek, Lutz, additional, Schaefer-Eckert, Kerstin, additional, Burchert, Andreas, additional, Corradini, Paolo, additional, Schubert, Joerg E. A., additional, Kaufmann, Martin, additional, Dreger, Peter, additional, Wulf, Gerald, additional, Stuhler, Gernot, additional, Kvasnicka, Hans-Michael, additional, Zander, Axel R., additional, Niederwieser, Dietger, additional, Brand, Ronald, additional, de Witte, Theo M., additional, and Kröger, Nicolaus, additional

Published
2011
Full Text
View/download PDF

42. Induction Chemotherapy Followed Immediately by Busulfan-Based Reduced Conditioning and Allografting in Elderly Patients with Advanced MDS or sAML.

Author

Kröger, Nicolaus, primary, Zabelina, Tatjana, additional, Wolschke, Christine, additional, Lellek, Heinrich, additional, Stübig, Thomas, additional, Lestin, Maite, additional, Alchalby, Haefaa, additional, Ayuk, Francis, additional, Bacher, Ulrike, additional, Fehse, Boris, additional, and Zander, Axel R., additional

Published
2009
Full Text
View/download PDF

43. Related Vs Unrelated Donors After Auto-Allo Tandem Stem Cell Transplantation for Newly Diagnosed Patients with Multiple Myeloma.

Author

Kröger, Nicolaus, primary, Zabelina, Tatjana, additional, Heinzelmann, Marion, additional, Schilling, Georgia, additional, Wolschke, Christine, additional, Lellek, Heinrich, additional, Stübig, Thomas, additional, Lestin, Maite, additional, Alchalby, Haefaa, additional, Ayuk, Francis, additional, Atanackovic, Djordje, additional, Bacher, Ulrike, additional, Fehse, Boris, additional, and Zander, Axel R., additional

Published
2009
Full Text
View/download PDF

45. JAK2-V617F–triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

Author

Kröger, Nicolaus, primary, Alchalby, Haefaa, additional, Klyuchnikov, Evgeny, additional, Badbaran, Anita, additional, Hildebrandt, York, additional, Ayuk, Francis, additional, Bacher, Ulrike, additional, Bock, Oliver, additional, Kvasnicka, Michael, additional, Fehse, Boris, additional, and Zander, Axel, additional

Published
2009
Full Text
View/download PDF

46. Assessment of bone marrow inflammation in patients with myelofibrosis: an F-fluorodeoxyglucose PET/CT study.

Author

Derlin, Thorsten, Alchalby, Haefaa, Bannas, Peter, Veldhoen, Simon, Apostolova, Ivayla, Triviai, Ioanna, Bengel, Frank, and Kröger, Nicolaus

Subjects
MYELOFIBROSIS, BONE marrow diseases, STEM cells, INFLAMMATION, FLUORODEOXYGLUCOSE F18, DISEASES
Abstract

Purpose: Myelofibrosis is a haematopoietic stem cell neoplasm characterized by bone marrow inflammation, reactive marrow fibrosis and extramedullary haematopoiesis. The aim of this study was to determine if F-FDG PET/CT can be used to noninvasively visualize and quantify the extent and activity of bone marrow involvement. Methods: In 30 patients, the biodistribution of F-FDG was analysed by measuring the standardized uptake value in the bone marrow compartment and spleen. Imaging findings were compared with laboratory, cytogenetic and histopathological data. Results: Retention of F-FDG was observed in bone marrow and spleen. Bone marrow involvement varied, ranging from mildly increased uptake in the central skeleton to extensive uptake in most parts of the skeleton. The extent of bone marrow involvement decreased over time from initial diagnosis ( r = −0.43, p = 0.019). Metabolic activity of the bone marrow decreased as the histopathological grade of fibrosis increased ( r = −0.37, p = 0.04). There was a significant positive correlation between the metabolic activity of the bone marrow and that of the spleen ( p = 0.04). Conclusion: F-FDG PET/CT is as a promising technique for the quantitation of bone marrow inflammation in myelofibrosis. Our data indicate that the intensity of bone marrow F-FDG uptake decreases as bone marrow fibrosis increases. Further evaluation in prospective studies is required to determine the potential clinical impact and prognostic significance of PET. [ABSTRACT FROM AUTHOR]

Published
2015
Full Text
View/download PDF

50. CD34+-Selected Stem Cell Boost without Further Conditioning for Poor Graft Function after Allogeneic Stem Cell Transplantation in Patients with Hematological Malignancies.

Author

Klyuchnikov, Evgeny, El-Cheikh, Jean, Sputtek, Andreas, Lioznov, Michael, Calmels, Boris, Furst, Sabine, Chabannon, Christian, Crocchiolo, Roberto, Lemarié, Claude, Faucher, Catherine, Bacher, Ulrike, Alchalby, Haefaa, Stübig, Thomas, Wolschke, Christine, Ayuk, Francis, Reckhaus, Marie-Luise, Blaise, Didier, and Kröger, Nicolaus

Subjects
*CD34 antigen, *STEM cell transplantation, *GRAFT versus host disease, *HEMATOLOGIC malignancies, *NEUTROPHILS, *HEMOGLOBINS
Abstract

Abstract: We retrospectively analyzed outcomes of a CD34+-selected stem cell boost (SCB) without prior conditioning in 32 patients (male/22; median age of 54 years; range, 20 to 69) with poor graft function, defined as neutrophils ≤1.5 x 109/L, and/or platelets ≤30 x 109/L, and/or hemoglobin ≤8.5 g/dL). The median interval between stem cell transplantation and SCB was 5 months (range, 2 to 228). The median number of CD34+ and CD3+ cells were 3.4 x 106/kg (.96 to 8.30) and 9 x 103/kg body weight (range, 2 to 70), respectively. Hematological improvement was observed in 81% of patients and noted after a median of 30 days (range, 14 to 120) after SCB. The recipients of related grafts responded faster than recipients of unrelated grafts (20 versus 30 days, P = .04). The cumulative incidence of acute (grade II to IV) and chronic graft-versus-host disease (GVHD) after SCB was 17% and 26%, respectively. Patients with acute GVHD received a higher median CD3+ cell dose. The 2-year probability of overall survival was 45%. We suggest that SCB represents an effective approach to improve poor graft function post transplantation, but optimal timing of SCB administration, anti-infective, and GVHD prophylaxis needs further evaluation. [Copyright &y& Elsevier]

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results